News & Updates

Show Multimedia Only

Cytisinicline confirmed to be efficacious, well-tolerated in smokers set to quit

31 May 2025 by

Cytisinicline’s efficacy and tolerability for smoking cessation has been validated in another large phase III trial conducted in the US, with both the 6- and 12-week treatments yielding positive benefits persisting through 24 weeks.

Cytisinicline confirmed to be efficacious, well-tolerated in smokers set to quit

31 May 2025

Internal tremors, vibrations pester people with long COVID

31 May 2025 by

Individuals with long COVID may experience internal tremors and vibrations, which can signal a worse health status compared with others without these symptoms, a study has shown.

Internal tremors, vibrations pester people with long COVID

31 May 2025

First-line atezolizumab plus CP/ET offers survival benefits in ES-SCLC

30 May 2025 by

Patients with extensive-stage small cell lung cancer (ES-SCLC) derive real-world clinical benefits from first-line treatment with atezolizumab combined with carboplatin and etoposide (CP/ET), reports a recent study.

First-line atezolizumab plus CP/ET offers survival benefits in ES-SCLC

30 May 2025

Inhaled sedation with sevoflurane not beneficial in moderate-to-severe ARDS

29 May 2025

In critically ill patients with moderate-to-severe acute respiratory distress syndrome (ARDS), inhaled sedation with sevoflurane may lead to fewer ventilator-free days at day 28 and lower 90-day survival compared with sedation with propofol, according to the results of the phase III SESAR study.

Inhaled sedation with sevoflurane not beneficial in moderate-to-severe ARDS

29 May 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-May-2025

29 May 2025

New drug applications approved by US FDA as of 1-15 May 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-May-2025

29 May 2025

β-lactam/β-lactamase inhibitor combination noninferior to piperacillin/tazobactam for pneumonia

28 May 2025

In the treatment of adults with hospital-associated (HABP) or ventilator-associated bacterial pneumonia (VABP), the β-lactam/β-lactamase inhibitor combination imipenem/cilastatin/relebactam appears to be as good as piperacillin/tazobactam, with similar safety profiles, according to a phase III trial.

β-lactam/β-lactamase inhibitor combination noninferior to piperacillin/tazobactam for pneumonia

28 May 2025

High, increasing BMI ups risk of adulthood OSA

26 May 2025 by

Individuals with high or continuously increasing BMI from childhood to middle age are at greater risk of developing obstructive sleep apnoea (OSA) later in life, reveals a study.

High, increasing BMI ups risk of adulthood OSA

26 May 2025

Personalizing upfront treatment options for advanced EGFRm NSCLC

26 May 2025 by

This article will summarize the latest developments in the first-line management of advanced EGFRm NSCLC and highlight key consideration factors.

Personalizing upfront treatment options for advanced EGFRm NSCLC

26 May 2025

VMR tied to severe COPD exacerbation

25 May 2025

Visceral fat-to-muscle ratio (VMR) can be used to predict the severe exacerbation of chronic obstructive pulmonary disease (COPD), suggests a study.

VMR tied to severe COPD exacerbation

25 May 2025

TrUST study heralds new era for TB diagnosis

21 May 2025 by

A suite of deep learning (DL) models to automate tuberculosis (TB) risk assessment from lung ultrasound (LUS) images fulfils the WHO criteria for a sputum-free TB triage test and outwits human experts in the TrUST study.

TrUST study heralds new era for TB diagnosis

21 May 2025

News & Updates

Filter by Specialty:

Specialty:

Cytisinicline confirmed to be efficacious, well-tolerated in smokers set to quit

Cytisinicline confirmed to be efficacious, well-tolerated in smokers set to quit

Internal tremors, vibrations pester people with long COVID

Internal tremors, vibrations pester people with long COVID

First-line atezolizumab plus CP/ET offers survival benefits in ES-SCLC

First-line atezolizumab plus CP/ET offers survival benefits in ES-SCLC

Inhaled sedation with sevoflurane not beneficial in moderate-to-severe ARDS

Inhaled sedation with sevoflurane not beneficial in moderate-to-severe ARDS

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-May-2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-May-2025

β-lactam/β-lactamase inhibitor combination noninferior to piperacillin/tazobactam for pneumonia

β-lactam/β-lactamase inhibitor combination noninferior to piperacillin/tazobactam for pneumonia

High, increasing BMI ups risk of adulthood OSA

High, increasing BMI ups risk of adulthood OSA

Personalizing upfront treatment options for advanced EGFRm NSCLC

Personalizing upfront treatment options for advanced EGFRm NSCLC

VMR tied to severe COPD exacerbation

VMR tied to severe COPD exacerbation

TrUST study heralds new era for TB diagnosis

TrUST study heralds new era for TB diagnosis